Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology
- Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody - Biosion earns a $10 million upfront license fee; additional milestone payments and royalties on commercial sales to be earned up...
2022-03-29 23:00
1825